Skip to Content


Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat




Even With Efforts Focused on COVID-19 Vaccine, BioNTech’s Pipeline in Cancer Progressing Nicely

Anna Baran Equity Analyst

Analyst Note

| Anna Baran |

We’re not changing our fair value estimate for no-moat BioNTech following its second-quarter results. While recent investor attention has been focused on the company’s development of a COVID-19 vaccine with partners Pfizer (ex-China) and Fosun Pharma (China), the earnings call highlighted other drugs in the pipeline that merit investor attention and will drive long-term growth for the company if approved.

Read Full Analysis

Company Profile

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, and does not yet have any commercialized medicines.

An der Goldgrube 12
Mainz, D-55131, Germany
T +49 613190840
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 1,310